Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis

OBJECTIVES: Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study descri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: den Braanker, Hannah, Wervers, Kim, Mus, Adriana M C, Bangoer, Priyanka S, Davelaar, Nadine, Luime, Jolanda, Tchetverikov, Ilja, Hazes, J M W, Vis, Marijn, Lubberts, Erik, Kok, Marc R
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Psoriatic Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425114/
https://ncbi.nlm.nih.gov/pubmed/32669451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001175
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados